Previous 10 | Next 10 |
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® PR Newswire SHANGHAI , March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® PR Newswire STOCKHOLM , March 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the ...
Calliditas Therapeutics to Attend Investor Conferences in March PR Newswire STOCKHOLM , March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases t...
2024-02-29 16:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-21 17:46:07 ET Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript February 21, 2024, 08:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
Calliditas Year-end report, January - December 2023 PR Newswire STOCKHOLM , Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes "In December we wer...
Invitation to the presentation of Calliditas´ Year-end report January - December 2023 PR Newswire STOCKHOLM , Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday ...
Calliditas provides patent update PR Newswire STOCKHOLM , Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no...
2024-01-28 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action PR Newswire STOCKHOLM , May 16, 2024 /PRNewswire/...
Invitation to the presentation of Calliditas´s interim report January - March 2024 PR Newswire STOCKHOLM , May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on ...
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm PR Newswire STOCKHOLM , May 15, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM : CALTX) ("Calliditas"), today announced upcoming data presenta...